Molecular biology

Combined CDC COVID-19/Influenza Test Amended to Include Promega Maxwell® RSC 48 and CSC 48 Instruments, Maxwell® RSC Viral Total Nucleic Acid Purification Kit

Retrieved on: 
Wednesday, January 13, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210113005075/en/
    The Promega Maxwell CSC 48 (pictured), Maxwell RSC 48 and Maxwell RSC Viral Total Nucleic Acid Purification Kit are now authorized options for labs running the US Centers for Disease Controls (CDC) Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay.
  • (Photo: Business Wire)
    The Promega Maxwell RSC 48 benchtop instrument is an automated nucleic acid purification platform that processes up to 48 samples simultaneously.
  • The Maxwell RSC Viral Total Nucleic Acid Purification Kit can be used with either instrument to purify viral RNA from SARS-CoV-2 test samples.
  • Maxwell RSC 48, Maxwell CSC 48, Maxwell RSC Viral Total Nucleic Acid Purification Kit and GoTaq Probe 1-Step RT-qPCR System are already included, for emergency use, in the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RTPCR Diagnostic Panel, which tests for COVID-19 only.

Oligonucleotide Therapeutics: Bridging from Research to Commercial, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, January 13, 2021

This webinar will examine potential CMC gaps that can occur between research and commercial stages, helping to improve project design and management.

Key Points: 
  • This webinar will examine potential CMC gaps that can occur between research and commercial stages, helping to improve project design and management.
  • Oligonucleotide development and manufacturing requires many particular capabilities, from specialized manufacturing centers and equipment to process and analytical methodology development, as well as technical expertise.
  • However, sponsors typically change oligonucleotide partners when moving from the research and discovery stage to preclinical/clinical stage as well as to the commercial stage.
  • For more information, or to register for this event, visit Oligonucleotide Therapeutics: Bridging from Research to Commercial.

Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

Retrieved on: 
Wednesday, January 13, 2021

Whole genome sequencing has the ability to significantly improve diagnosis for a wide range of diseases and guide healthcare throughout life.

Key Points: 
  • Whole genome sequencing has the ability to significantly improve diagnosis for a wide range of diseases and guide healthcare throughout life.
  • We believe this world-class sequencing technology combined with our clinical capabilities will uniquely position us to deliver those benefits cost effectively at scale.
  • We look forward to working with the PacBio team to develop a new generation of innovative whole genome-based offerings.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.

Taysha Gene Therapies and UT Southwestern Medical Center Launch Innovation Fund to Accelerate Advancement of AAV Gene Therapies for Monogenic Diseases of the Central Nervous System

Retrieved on: 
Wednesday, January 13, 2021

Taysha will have an exclusive option on new programs and intellectual property associated with, and arising from, the research conducted under this agreement.

Key Points: 
  • Taysha will have an exclusive option on new programs and intellectual property associated with, and arising from, the research conducted under this agreement.
  • A team of researchers from the gene therapy program at UT Southwestern will explore novel gene therapy targets in new disease areas and create next-generation gene therapy technology platforms to address some of the current limitations of this modality.
  • UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education.
  • Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease.

Global Bacterial and Plasmid Vectors Market Report 2020-2030 Featuring Sigma-Aldrich, ATUM, QIAGEN, Promega, Thermo Fisher Scientific, GenScript Biotech, Takara Bio, and New England Biolabs

Retrieved on: 
Wednesday, January 13, 2021

Major players in the bacterial and plasmid vectors market are Sigma-Aldrich Inc., ATUM, QIAGEN, Promega Corporation, Thermo Fisher Scientific, Inc., GenScript Biotech Corporation, Takara Bio Inc., IBA GmbH, Bio-Rad Laboratories and New England Biolabs.

Key Points: 
  • Major players in the bacterial and plasmid vectors market are Sigma-Aldrich Inc., ATUM, QIAGEN, Promega Corporation, Thermo Fisher Scientific, Inc., GenScript Biotech Corporation, Takara Bio Inc., IBA GmbH, Bio-Rad Laboratories and New England Biolabs.
  • The bacterial and plasmid vectors market consists of sales of bacterial and plasmid vectors and related services by entities (organizations, sole traders and partnerships) that develop bacterial and plasmid vectors for biotechnological applications.
  • Global Bacterial and Plasmid Vectors Market, Segmentation by Host Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
    4.2.
  • Global Bacterial and Plasmid Vectors Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®

Retrieved on: 
Wednesday, January 13, 2021

Meanwhile, topline results for a third Phase III trial, REFLECT, are expected in Q2 2021.

Key Points: 
  • Meanwhile, topline results for a third Phase III trial, REFLECT, are expected in Q2 2021.
  • As in the REVERSE trial, one eye received LUMEVOQ gene therapy through an intravitreal injection while the other eye received a sham injection.
  • The subjects were followed for 96 weeks after their injection; topline results at Week 96 were reported in 2019.
  • Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.

GT Molecular launches two highly sensitive tests for the dangerous UK Variant of SARS-CoV-2 (B.1.1.7)

Retrieved on: 
Tuesday, January 12, 2021

Research labs doing their own community testing, environmental testing labs, CLIA labs, Health officials

Key Points: 
  • Research labs doing their own community testing, environmental testing labs, CLIA labs, Health officials
    SARS-CoV-2 UK variant testing now available as a fee-for-service and as a complete PCR kit for testing labs!
  • By applying this method of community wastewater monitoring to the newly circulating UK variant, GT Molecular is the first to go one step further and actually "genotype the sewer".
  • These new tests enable GT Molecular to provide communities, researchers and wastewater treatment operations across the U.S. with the latest information about the new COVID-19 variant.
  • Whether it be cancer, GMO or harmful pathogens, GT Molecular (GTM) is a leader in providing highly customizable, ultrasensitive digital PCR and qPCR tests for researchers and the Molecular Diagnostics community.

New England Biolabs Expands its Luna® Portfolio with the SARS-CoV-2 RT-qPCR Multiplex Assay Kit

Retrieved on: 
Tuesday, January 12, 2021

IPSWICH, Mass., Jan. 12, 2021 /PRNewswire/ --New England Biolabs (NEB) today announced the launch of its LunaSARS-CoV-2 RT-qPCR Multiplex Assay Kit for real-time detection of SARS-CoV-2 nucleic acid.

Key Points: 
  • IPSWICH, Mass., Jan. 12, 2021 /PRNewswire/ --New England Biolabs (NEB) today announced the launch of its LunaSARS-CoV-2 RT-qPCR Multiplex Assay Kit for real-time detection of SARS-CoV-2 nucleic acid.
  • "To address this, we specifically developed the Luna SARS-CoV-2 RT-qPCR Multiplex Assay Kit by modifying the Centers for Disease Control and Prevention (CDC)-designed RNase P control reverse primer to avoid spurious amplification of human genomic DNA.
  • "With these enhancements, the kit achieves strong multiplex detection with 24 hours of room temperature stability.
  • Luna, NEB, and NEW ENGLAND BIOLABS are registered trademarks of New England Biolabs, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/new-england-biolabs-expands-its-...

Global Viral Vectors & Plasmid DNA Market Report 2020-2023 & 2030 with Focus on COVID-19 Implications and Growth

Retrieved on: 
Tuesday, January 12, 2021

DUBLIN, Jan. 12, 2021 /PRNewswire/ -- The "Viral Vectors & Plasmid DNA Global Market Report 2020-30: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 12, 2021 /PRNewswire/ -- The "Viral Vectors & Plasmid DNA Global Market Report 2020-30: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.
  • Viral Vectors & Plasmid DNA Global Market Report 2020-30: COVID-19 Implications and Growth provides the strategists, marketers and senior management with the critical information they need to assess the global viral vectors & plasmid dna market.
  • The viral vectors & plasmid DNA market consists of sales of viral vectors & plasmid DNA and related services.
  • The viral vectors & plasmid DNA market covered in this report is segmented by product into plasmid DNA; viral vectors and by applications into gene and cancer therapies; viral infections; immunotherapy; formulation development; others.

Cardea Bio Adds $6.5 Million to Series A; Early-Stage Financing Now Totals More Than $20 Million

Retrieved on: 
Tuesday, January 12, 2021

The new capital infusion is led by the life sciences and biotechnology focused investor 3E Bioventures Capital and joined by existing investors.

Key Points: 
  • The new capital infusion is led by the life sciences and biotechnology focused investor 3E Bioventures Capital and joined by existing investors.
  • Cardeas proprietary technology enables ultra-sensitive and direct detection of molecular analytes without requiring normal sample preparations and amplification steps such as PCR or protein labeling.
  • 2020 was a very productive year in spite of COVID, said Rob Lozuk, Chief Business Officer of Cardea.
  • For more information about Cardea Bio Inc. visit www.cardeabio.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005429/en/